Austria targets global drugmaker in abuse case
Credit: Tibor Duris/Shutterstock
Austria’s Federal Competition Authority has accused an unnamed drug manufacturer of charging predatory prices for a cancer medicine, so as to dissuade hospitals from switching to rival generic brands.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now